Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

The Profit Potential From U.S. General Anesthesia Drugs Business Is Massive

The U.S. general anaesthesia drugs market is dominated by players such as Hikma Pharmaceuticals PLC (U.K.), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Published Report @

Acquisitions is the most-preferred growth strategy adopted by key players in the U.S. general anaesthesia drugs market in order to increase their market shares, cater to customers' demands, and consolidate their market presence. For instance, in May 2014, Fresenius Kabi, business Unit of Fresenius Se & Co. KGaA, entered into an agreement to acquire the privately held Brazilian pharmaceutical company-Novafarma IndĂșstria FarmacĂȘutica Ltda. Novafarma manufactures a comprehensive range of generic I.V. drugs, including antibiotics, analgesics, and anaesthetics for the Brazilian hospital market.

Sample PDF Pages @

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. general anaesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anaesthetic drugs are likely to restrain the growth of this market.

The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anaesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anaesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anaesthetics are driving the growth of this market.